Table 3

 Base case scenario

CharacteristicMethotrexateGoldLeflunomideEtanercept
Route of administrationPOIMPOSC
Physician experience (years)>20>20NewNew
Onset of action (weeks)4842
Percentage who benefit60606075
Percentage without new bone erosions60606075
Injection site reaction (%)00040
Rash (%)1040100
Oral ulcers (%)1010100
Alopecia (%)100100
Nausea (%)100100
Diarrhoea (%)100200
Cancer0001/1000
Renal toxicity01/10000
Hepatic toxicity1/100001/10000
Pneumonitis1/1001/100000
Co-pay ($)5.005.005.005.00